Inflammatory bowel disease (IBD) begins usually between 20 and 30. A second peak in incidence between 50 and 70 has been recognized. IBD in the elderly is defined as disease diagnosed after the age of 60. IBD in the elderly are special entity, characterized by their weakness, associated comorbidity, and their sometimes-severe course. The aim of this study was to investigate the epidemiological, clinical, therapeutic and evolutionary particularities of IBD in elderly. This is a retrospective study over a 5-year period from July 2018 to July 2023 on 424 patients followed for IBD. We included patients with documented CD or UC and who are over 60 years of age at the time of diagnosis. Of the 16 patients enrolled, mean age at diagnosis was 69.48 [60-82], sex ratio F/M 1.28, 2 patients were smokers (12.5%), 13 (81.25%) had at least one associated comorbidity. 7 patients had CD (43.75%), 7 had UC (43.75%), and 2 had indeterminate colitis (12.5%). 3 patients underwent surgery (18.75%), 2 for severe acute colitis with subtotal colectomy and ileorectal anastomosis, and 1 for ileal fistulas with ileocecal resection and ileocolic anastomosis. The progression was favorable, with an average number of relapses of 2/year, and an average number of severe relapses of 0.5/year. Maintenance of remission was noted in 15 cases (93.75%). 8 patients were on 5-Aminosalicylates (5ASA) (50%), corticosteroids and immunosuppressives was prescribed in 4 patients (25%), anti-TNFs in 2 patients (12.5%), anti-interleukins 1 patient (6.25%) and 1 patient was in remission on no treatment. In conclusion, the disease localization and phenotype in this study are like those reported in the literature relating to elderly IBD patients, and despite concerns about the risk of acquiring infections and malignancies in this age group, a high rate of corticosteroids and immunosuppressive prescription is noted.